Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
Crossref DOI link: https://doi.org/10.1007/s00280-014-2583-9
Published Online: 2014-09-13
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fabre, Claire
Gobbi, Marco
Ezzili, Cyrine
Zoubir, Mustapha
Sablin, Marie-Paule
Small, Karen
Im, Ellie
Shinwari, Nabeegha
Zhang, Da
Zhou, Honghong
Le Tourneau, Christophe
Text and Data Mining valid from 2014-09-13